Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib
Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with
Metastatic Colorectal Carcinoma(CRC) as 1st Therapy. After 6 cycles of combined therapy,
patients will receive capecitabine and anlotinib as maintenance therapy until tumor
progression.In order to observe and evaluate the efficacy and safety of Anlotinib
Hydrochloride Capsules combined with CAPEOX in treatment of patients with mCRC. The patients
who are pathologically confirmed as RAS and BRAF wild-type mCRC will be enrolled.
Condition or disease Invention/treatment Phase Colorectal Cancer Drug: Anlotinib
Hydrochloride Drug: Capecitabine Drug: Oxaliplatin Phase 2